Study on XL092 with Immunotherapy for Patients with Clear Cell Kidney Cancer After Previous Treatment

Inclusion Criteria

• Must be 18 years or older.
• Have a confirmed diagnosis of advanced or metastatic clear cell kidney cancer.
• Cancer must have worsened after receiving standard immunotherapy (anti-PD-1/PD-L1) and no other systemic therapy.
• Must have measurable disease based on specific medical criteria.
• Must have completed previous cancer treatment at least 2 weeks before starting the study and recovered from any side effects.
• Must have adequate organ function as shown by specific blood tests.
• Women of childbearing potential must have a negative pregnancy test and agree to use effective contraception.
• Men must agree to use effective contraception if sexually active with a woman of childbearing potential.
• Patients with controlled HIV, hepatitis B, or hepatitis C infections may be eligible.
• Must be able to understand and agree to follow study procedures.

Exclusion Criteria

• Recent radiation therapy or ongoing complications from previous radiation.
• Known brain metastases unless treated and stable.
• Use of certain complementary medicines within 2 weeks before starting the study.
• Active infection requiring treatment.
• Positive TB test with active infection.
• Pregnant or breastfeeding women.
• Severe allergic reactions to study drugs.
• Other cancers that could interfere with the study.
• Recent live vaccine.
• Certain lung diseases or history of lung inflammation.
• Prior organ transplant.
• Inability to swallow pills.
• Uncontrolled major health issues.
• Recent blood clots or heart issues.
• Certain gastrointestinal disorders.
• Significant bleeding history.
• Other serious health conditions that could affect participation.